 |
Zebrafish platelets respond predictably to Thrombotics and Anti-Thrombotics. |
 Control with no ADP (1.5 MB movie) |
 Untreated + ADP (1.2 MB movie) |
 Pretreated with Aspirin + ADP (1.7 MB movie) |
 Play Quicktime Movie |
Play Quicktime Movie |
Play Quicktime Movie |
Note: The movies on this site require the Quicktime Player to view. If you do not have the QuickTime Player, click here to download. Movies may take some time to load before playing.
Since current thrombosis drugs are hampered by serious side effects such as bleeding, drugs that target novel mechanisms of action are of great interest. Zygogen has developed in vivo thrombosis assays using a Z-TagSM fish with fluorescent thrombocytes, the equivalent of mammalian platelets. Application of thrombotic agonists, such as ADP, thrombin and collagen type 1, cause platelet aggregation in vivo, which is easily visualized using platelet-specific fluorescent larvae. Clinical anti-thrombotic drugs, such as aspirin, ticlopidine, ReoPro®, Aggrastat® and Integrilin®, are effective in preventing ADP-induced platelet aggregation, suggesting the conservation of zebrafish and human thrombosis events.